

MILBEMAX 12.5 MG/125 MG TABLETS FOR DOGS

Authorised

- Milbemyacin oxime
- Praziquantel

Product identification

Medicine name:

MILBEMAX 12.5 MG/125 MG TABLETS FOR DOGS

Active substance:

Milbemyacin oxime

Praziquantel

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Milbemyacin oxime

12.50 milligram(s) / 1.00 Tablet

Praziquantel

125.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QP54AB51

Legal status of supply:

Veterinary medicinal product not subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Netherlands

Available in:

Netherlands

Package description:

Box of 1 PVC/PE/PVdC/aluminium blister of 2 tablets
Box of 10 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 5 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 2 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 1 PVC/PE/PVdC/aluminium blister of 10 tablets
Box of 1 PVC/PE/PVdC/aluminium blister of 4 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Elanco GmbH

Marketing authorisation date:

8/07/2003

Manufacturing sites for batch release:

Elanco France S.A.S.

Responsible authority:

Medicines Evaluation Board

Authorisation number:

REG NL 10091

Date of authorisation status change:

7/04/2022

Reference member state:

France

Procedure number:

FR/V/0135/002

Concerned member states:

Austria Belgium Cyprus Czechia Denmark Finland Germany Greece
Hungary Ireland Italy Luxembourg Netherlands Norway Poland Portugal
Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 7/02/2025

Updated on: 14/03/2026

Download